Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Stomach Cancer


 FAME                                                  gastric(61)
 _________________________________________________________________
  fluorouracil.... 350 mg/sqm/day IV on days 1 to 5; 

                   and on days 36 to 40.
  adriamycin...... 40 mg/sqm IV on days 1 and 36.
  semustine....... 150 mg/sqm orally on day 1.
  FREQUENCY....... Repeat cycle every 10 weeks.

  reference...
    Anonymous. Phase II-III chemotherapy studies in advanced 
    gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 
    Treatment Reports.  63(11-12):1871-6, 1979 Nov-Dec. 
  abstract...
      In this multi-institutional study of advanced gastric 
    cancer, 141 eligible and evaluable patients were treated with 
    either (a) Adriamycin alone, (b) a combination of 
    5-fluorouracil, Adriamycin, and methyl-CCNU (FAMe), or (c) a 
    combination of 5-fluorouracil, mitomycin C, and cytosine 
    arabinoside (FMC). In patients with measurable disease and no 
    prior chemotherapy, objective responses were seen in four of 
    17 patients (24%) receiving Adriamycin alone, in seven of 15 
    (47%) receiving FAMe, and in three of 18 (17%) receiving FMC. 
    In previously treated patients with measurable disease, 
    objective responses were seen in three of 17 patients (18%) 
    receiving Adriamycin alone and in one of 11 (9%) receiving 
    FMC. In previously untreated patients with both measurable and 
    nonmeasurable disease, FAMe showed a significant advantage 
    over both Adriamycin alone and FMC with regard to interval to 
    disease progression and survival. In comparing Adriamycin 
    alone with FMC in previously treated patients, intervals to 
    disease progression and survival were essentially identical. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.